A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (NCT07545759)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Who can join: Review the eligibility criteria below.
Location: Del Sol Research Management - Mesa — Mesa, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- Del Sol Research Management - Mesa — Mesa, Arizona
- Smart Cures Clinical Research — Anaheim, California
- Om Research LLC — Lancaster, California
- United Medical Doctors - Los Alamitos — Los Alamitos, California
- Encore Medical Research — Hollywood, Florida
- Clinical Research of Osceola — Kissimmee, Florida
- Springfield Clinic - First — Springfield, Illinois
- Gastroenterology Health Partners — New Albany, Indiana
- Gastroenterology Health Partners — Louisville, Kentucky
- Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center — Wyoming, Michigan
- Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
- Ohio Gastroenterology — Columbus, Ohio
- University Gastroenterology — Providence, Rhode Island
- Biopharma Informatic, LLC — McAllen, Texas
- Southern Star Research Institute — San Antonio, Texas
- Sint Vincentius Ziekenhuis — Antwerp,
- AZ Sint-Lucas — Bruges,
- UZ Brussel — Brussels,
- Antwerp University Hospital — Edegem,
- AZ Maria Middelares — Ghent,
- AZ Sint-Lucas — Ghent,
- UZ Gent — Ghent,
- UZ Leuven — Leuven,
- Clinical Chc Montlégia — Liège,
- AZ Delta vzw — Roeselare,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Irritable Bowel Syndrome
- Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) — Boston, Massachusetts
- Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome — Philadelphia, Pennsylvania
- A Well-Being Intervention for People With IBS — Madison, Wisconsin
- Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome — Camden, New Jersey
- Defining Objective Markers of Compliance for Dietary Therapies in IBS — Ann Arbor, Michigan
- Mucosal and Microbiota Changes During Acute Campylobacteriosis — Rochester, Minnesota
Explore by condition: All Irritable Bowel Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.